Rakovina Therapeutics receives government grant to accelerate novel cancer therapy program

Rakovina Therapeutics chief scientific officer Mads Daugaard joined Proactive's Steve Darling to share news the company is receiving research and development funding from the National Research Council of Canada Industrial Research Assistance Program.

Daugaard tells Proactive the non-dilutive financing will provide its scientists in the development of DNA-damage response inhibitors with the goal of selecting one or more lead compounds for advancement to either toxicology and/or investigational new drug studies.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com